Pseudomembranous colitis associated with a triple therapy for *Helicobacter pylori* eradication

Anca Trifan, Irina Girleanu, Camelia Cojocariu, Catalin Sfarti, Ana Maria Singeap, Carmen Dorobat, Lucia Grigore, Carol Stanciu

Anca Trifan, Irina Girleanu, Camelia Cojocariu, Catalin Sfarti, Ana Maria Singeap, Carmen Dorobat, Lucia Grigore, “Gr. T. Popa” University of Medicine and Pharmacy, 700111 Iasi, Romania

Anca Trifan, Camelia Cojocariu, Catalin Sfarti, Ana Maria Singeap, Carol Stanciu, Institute of Gastroenterology and Hepatology, “St. Spiridon” Emergency Hospital, 700111 Iasi, Romania

Carmen Dorobat, Lucia Grigore, “St. Parascheva” Clinical Hospital of Infectious Diseases, 700111 Iasi, Romania

Author contributions: Trifan A and Stanciu C co-wrote the manuscript; Cojocariu C, Singeap AM, Dorobat C and Grigore L managed the patients; Girleanu I and Sfarti C contributed to the acquisition of data; all authors read and approved the final version of the manuscript.

Correspondence to: Carol Stanciu, MD, PhD, FRCP, Institute of Gastroenterology and Hepatology, “St. Spiridon” Emergency Hospital, Independentei 1, 700111 Iasi, Romania. carolstanciu@yahoo.com

Telephone: +40-722-306020 Fax: +40-232-264411

Received: June 5, 2013 Revised: August 18, 2013

Accepted: September 15, 2013

Published online: November 14, 2013

Abstract

*Helicobacter pylori* (*H. pylori*) is one of the most common chronic bacterial infections in humans, affecting half of world’s population. Therapy for *H. pylori* infection has proven to be both effective and safe. The one-week triple therapy including proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole is still recommended as a first-line treatment to eradicate *H. pylori* infection. A limited colonoscopy showed typical appearance of pseudomembranous colitis, and the stool test for *Clostridium difficile* toxins was positive. Rapid resolution of symptoms and negative *C. difficile* toxins were obtained in both patients with oral vancomycin. No relapse occurred during a four and eleven-month, respectively, follow up. These cases suggest that physicians should have a high index of suspicion for pseudomembranous colitis when evaluate patients with diarrhea following *H. pylori* eradication therapy.

Key words: *Helicobacter pylori* eradication; Triple therapy; *Clostridium difficile*; Pseudomembranous colitis; Vancomycin

Core tip: Herein are described the cases of two elderly women who developed pseudomembranous colitis after one-week triple therapy consisting of pantoprazole (20 mg *bid*), clarithromycin (500 mg *bid*), and amoxicillin (1 g *bid*) to eradicate *Helicobacter pylori* (*H. pylori*) infection. After a 10-d treatment with oral vancomycin (125 mg every 6 h) both patients had complete resolution of symptoms and negative stool test for *Clostridium difficile* toxins. Clinicians should have a high index of suspicion of pseudomembranous colitis as a rare, but severe complication of *H. pylori* therapy.

Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, Grigore L, Stanciu C. Pseudomembranous colitis associated with a triple therapy for *Helicobacter pylori* eradication. *World J Gastroenterol* 2013; 19(42): 7476-7479 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i42/7476.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i42.7476
INTRODUCTION

*Helicobacter pylori* (H. pylori) is one of the most common chronic bacterial infections in humans, affecting half of the world’s population. Its prevalence is high in developing countries and low in the developed ones[3]. *H. pylori* eradication therapy is supported by numerous consensus groups around the world, and the treatment of millions of infected subjects has demonstrated that such strategy is both effective and safe. The spectrum of indications for *H. pylori* eradication therapy has steadily extended over the last decade[5] with a resultant increase in its use. The one-week triple therapy including proton pump inhibitor (PPI), clarithromycin and amoxicillin or metronidazole proposed at the first Maastricht conference[6] to eradicate *H. pylori* is still recommended as the first-line treatment by the recent Maastricht IV consensus conference[7] in countries with clarithromycin resistance rate under 15%-20% (e.g., Northern European countries)[8]. Eradication rates with standard triple therapy have fallen to 70%-80% over the past few years, mainly due to increasing resistance to clarithromycin[9]. Generally, this therapy is well-tolerated, with only a few and usually minor side effects (e.g., nausea, metallic taste). However, severe adverse effects such as pseudomembranous colitis have been reported[10], *Clostridium difficile* (*C. difficile*) being the main causative agent in all cases.

We report the cases of two elderly women who developed pseudomembranous colitis after one-week triple therapy with pantoprazole, clarithromycin, and amoxicillin for *H. pylori* infection.

CASE REPORT

The first case is a 70-year-old woman who was referred to our department with a 10-d history of watery diarrhea (6-12 stools per day) and crampy abdominal pain. Her medical history included hypertension, chronic gastritis *H. pylori* positive, and colonic diverticulosis (previously diagnosed on colonoscopy). Three weeks before admission she completed a one-week triple therapy (pantoprazole 20 mg bid, clarithromycin 500 mg bid and amoxicillin 1 g bid) for *H. pylori* infection. On physical examination, she looked unhealthy, and her abdomen was mildly tender, with no masses. Temperature and vital signs were normal. Laboratory investigations revealed leukocytosis (14800/mm$^3$) with neutrophilia, high C-reactive protein (11.5 mg/dL), and low levels of serum albumin (2.4 mg/dL), sodium (133 mEq/L), and potassium (2.7 mEq/L). Two days before admission, stool samples examination excluded enteric bacterial pathogens (*Shigella*, *Salmonella*, *Yersinia* spp.) as well as *C. difficile* toxins. Without any prior preparation, the patient underwent a limited colonoscopy, which showed diffusely scattered off-white pseudomembranes attached to the hyperemic underlying mucosa and multiple diverticula (Figure 1). Repeated stool sample examination was positive for *C. difficile* toxins A and B. Treatment with oral metronidazole 500 mg every 8 h was initiated, replaced 72 h later with oral vancomycin 125 mg every 6 h due to unfavorable response. After a 10-d treatment with vancomycin, the patient had a complete resolution of the symptoms and was discharged from hospital with negative results for *C. difficile* toxins and one stool per day. During a four-month follow-up, patient remained asymptomatic.

The second case concerns a 71-year-old woman who was admitted with profuse watery diarrhea (up to 10 stools daily) and abdominal pain. Her prior medical history was unremarkable. Symptoms occurred 5 d after a one-week triple therapy (pantoprazole 20 mg bid, clarithromycin 500 mg bid and amoxicillin 1 g bid) for *H. pylori* eradication. Physical examination was normal, except for signs of dehydration. Microbiological examination of stools was negative for *Salmonella*, *Shigella* and *Yersinia* spp., and did not reveal any parasites. The patient had leukocytosis (12400/mm$^3$), hypokalemia (2.8 mEq/L), and mild inflammatory syndrome. Sigmoidoscopy revealed scattered off-white pseudomembranes, some of them around a diverticulum.

**Figure 1** Pre-treatment endoscopic examination. Colonoscopy revealed scattered off-white pseudomembranes, some of them around a diverticulum.

**DISCUSSION**

Eradication therapy for *H. pylori* provides enormous benefits and has proved to be both effective and safe. Except from the rare and mild side-effects, eradication therapy is generally well-tolerated. Severe adverse effects such as pseudomembranous colitis following eradication therapy have very rarely been reported[6-13] which is quite surprising, taken into account the immense number of subjects treated worldwide. It is difficult to find a clear explanation why are so rare cases of pseudomembranous colitis after eradication therapy reported in the literature, but some hypotheses were put forward: (1) the use of metronidazole, an efficient drug against *C. difficile*, however, several cases of pseudomembranous colitis, as published, occurred after a regimen containing metronidazole[8,10], (2) the short duration of the therapy; (3) almost all treat-
ments are carried out in outpatients (hospitalization is a risk factor for *C. difficile* infection); and (4) many cases with mild clinical disease were most likely not diagnosed, either because the patients did not consult a physician or the physician did not suspect the development of *C. difficile* infection.

Over the last decade, *C. difficile* infection rate has increased dramatically worldwide both in incidence and severity. In addition to broad-spectrum antibiotic therapy, there have been identified many other potential risk factors for *C. difficile* infection (advanced age, female gender, comorbidities, admission to ICU, long hospital stay, immunosuppressive therapy, and PPI use). Several studies and recent meta-analyses have shown that PPI therapy is associated with increased risk of *C. difficile* infection and United States Food and Drug Administration even issued a safety announcement to inform the public about this possible risk. Newly published studies have found that *C. difficile* infection can occur outside the above mentioned well-known risk groups, in the absence of any hospitalization and even in young patients with no comorbidities.

All the components of the triple eradication therapy for *H. pylori* (PPI and two antibiotics: clarithromycin and amoxicillin or metronidazole) are potential risk factors for *C. difficile* infection. The most responsible for development of pseudomembranous colitis seems to be clarithromycin, used in both our cases and in most of the published reports.

The spectrum of *C. difficile* infection is wide, ranging from mild, self-limiting diarrhea to fulminant pseudomembranous colitis which is associated with significant morbidity and mortality. Most patients with *C. difficile* infection have a mild-to-moderate disease, but some may develop severe forms of disease such as pseudomembranous colitis, or even complicated by toxic megacolon.

Among variables used to define severe disease, the most important are the presence of pseudomembranes at endoscopy and age over 65 years. Both our cases met the criteria for a severe form of disease, and were treated with vancomycin according to current guidelines recommendations.

Our cases, in addition to the ones published, demonstrate that pseudomembranous colitis can occur after a usually well-tolerated triple therapy for *H. pylori* eradication. Despite this very rare complication, it should be underlined that *H. pylori* eradication therapy provides huge benefits and remains effective and generally safe. However, *C. difficile* infection may occur with an eradication therapy for *H. pylori* consisting of two antibiotics and a PPI. Most likely, *C. difficile* infection cases following *H. pylori* eradication therapy are not as rare as reported by literature, considering that a significant proportion of mild form of disease does not come to physician's attention and thus may remain undiagnosed.

Clinicians should be aware of such complication when prescribing triple therapy for *H. pylori* eradication, and should inform the patients that they may have diarrhea during or after treatment, and therefore should seek medical advice.

In conclusion, pseudomembranous colitis should be suspected in any patient with watery diarrhea during or after triple therapy for *H. pylori* eradication. Awareness of such complication is particularly important in the actual context when both duration and indications for *H. pylori* eradication therapy have been extended.

REFERENCES

1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304 [PMID: 21961099 DOI: 10.1097/MGG.0b013e31820f8616]

2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensis G, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302864]

3. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997; 41: 8-13 [PMID: 9274464]

4. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007; 56: 1502 [PMID: 17993840 DOI: 10.1136/gut.2007.132514]

5. Graham DY, Fischbach L. Helicobacter pylori therapy in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20529569 DOI: 10.1136/gut.2009.192757]

6. Teare JP, Booth JC, Brown JL, Martin J, Thomas HC. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol 1995; 7: 275-277 [PMID: 7743311]

7. Schweigart U, Franck H, Schepp W, Lehn N, Becker K, Classen M. Toxic megacolon after Helicobacter pylori eradication therapy. Internist (Berl) 1997; 38: 352-354 [PMID: 9213574]

8. Archimandritis A, Souyioutzis S, Katsorisa M, Tzivras M. Clostridium difficile colitis associated with a ‘triple’ regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori, Intern Med 1998; 243: 251-253 [PMID: 9627163 DOI: 10.1016/j.1365-2969.1998.00272.x]

9. Nawaz A, Mohammed I, Ahsan K, Karakurum A, Hadjiyane C, Pelleccchia C. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Ann J Gastroenterol 1998; 93: 1175-1176 [PMID: 9672359]

10. Harsch IA, Hahn EG, Konturek PC. Pseudomembranous colitis after eradication of Helicobacter pylori infection with a triple therapy. Med Sci Monit 2001; 7: 751-754 [PMID: 11433206]

11. Lau CF, Hui PK, Fung TT, Tung SY, Wong AM, Loo CK, Lam KM. Pseudomembranous colitis without diarrhea following Helicobacter pylori eradication therapy. Hosp Med 2001; 62: 431-433 [PMID: 11480134]

12. Rai R, Rai S. Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication. ANZ J Surg 2002; 72: 917-919 [PMID: 12485235 DOI: 10.1016/j.ans.2002.05.021]

13. Kubo N, Kochi S, Arikaya M, Murata M, Furusyo N, Hayashi H. Pseudomembranous colitis after Helicobacter pylori eradication therapy. Kansenshogaku Zasshi 2006; 80: 51-55 [PMID: 16519125]

14. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26 [PMID: 21119612 DOI: 10.1038/
15 O'Donoghue C, Kyne L. Update on Clostridium difficile infection. *Curr Opin Gastroenterol* 2011; 27: 58-47 [PMID: 21099432 DOI: 10.1097/MOG.0b013e328341634]

16 Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. *Expert Rev Gastroenterol Hepatol* 2010; 4: 409-416 [PMID: 20678014 DOI: 10.1586/egr.10.48]

17 Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, Slymen D, Lederman ER. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. *Clin Infect Dis* 2011; 53: 1173-1178 [PMID: 21976459 DOI: 10.1093/cid/cir669]

18 Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, Fraser VJ. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. *Arch Intern Med* 2007; 167: 1092-1097 [PMID: 17533213 DOI: 10.1086/52582]

19 Kuntz JL, Chrishilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. *BMJ Infect Dis* 2011; 11: 19 [PMID: 21762504 DOI: 10.1186/1471-2334-11-194]

20 Al-Turehi FI, Hassanou A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. *J Am Med Dir Assoc* 2005; 6: 105-108 [PMID: 15871884 DOI: 10.1016/j.jamda.2005.01.003]

21 Dalton BR, Lye-Maccannell T, Henderson EA, MacCannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. *Aliment Pharmacol Ther* 2009; 29: 626-634 [PMID: 19183143 DOI: 1111/j.1365-2036.2008.03924.x]

22 Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. *Am J Gastroenterol* 2008; 103: 2308-2313 [PMID: 18702653 DOI: 10.1111/j.1572-0241.2008.01975.x]

23 Linney S, Fernandes T, Einaron T, Sengar A, Walker JH, Mills A. Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. *Can J Hosp Pharm* 2010; 63: 31-37 [PMID: 22478951]

24 Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012; 107: 1011-1019 [PMID: 22525304 DOI: 10.1038/ajg.2012.108]

25 Deshpande A, Pan C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. *Clin Gastroenterol Hepatol* 2012; 10: 225-233 [PMID: 22019794 DOI: 10.1016/j.cgh.2011.09.030]

26 Tielyeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, Khan AR, Al Tennir M, Erwin P, Ibrahim T, Allebibi A, Badour LM, Sutton AJ. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. *PLoS One* 2012; 7: e50836 DOI: 10.1371/journal.pone.0050836

27 Howell MD, Novack V, Grgrich P, Souliard D, Novack L, Pencina M, Talmon D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. *Arch Intern Med* 2010; 170: 784-790 [PMID: 20458886 DOI: 10.1001/archinternmed.2010.89]

28 US Food and Drug Administration. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) 2012. RDA Drug Safety Communication, Rockville, MD, USA, accessed March 2012. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm

29 Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. *Am J Gastroenterol* 2012; 107: 89-95 [PMID: 22108454 DOI: 10.1038/ajg.2011.398]

30 Surawicz CM, Brandt LJ, Bionon DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *Am J Gastroenterol* 2013; 108: 478-98; quiz 499 [PMID: 23439232 DOI: 10.1038/ajg.2013.4]

31 Alcalá L, Martín A, Marín M, Sánchez-Somolinos M, Catalán P, Pelaez T, Bouza E. Spanish Clostridium difficile Study Group. The undiagnosed cases of Clostridium difficile infection in inpatient and outpatient settings. *Clin Gastroenterol Hepatol* 2012; 18: E204-E213 [PMID: 22563775 DOI: 1111/j.1469-0691.2012.03883]
